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Is Homocysteine a Risk
Factor for Atherothrombotic
Cardiovascular Disease?
In a recent state-of-the-art study, Kaul et al. (1) have not validated
the hypothesis of homocysteine as a risk factor for atherothrom-
botic cardiovascular disease. These conclusions will have major
implications for the developing countries that derive cutting-edge
knowledge of cardiovascular disease from the West (2).
There is consistency in the mean homocysteine level in patients
with coronary artery disease (CAD) from Pakistan and India of
about 19 mol/l (3–8). This finding is significant because the
South Asian population has the highest known rate of CAD,
which is widespread, early onset, and is aggressive (9). They have
higher propensity for clinical events compared with other popula-
tions even after adjusting for all known risk factors and the degree
of atherosclerosis (10).
The concept of homocysteine being a proximate risk factor with
short incubation period and its strong interaction with conven-
tional risk factors provides a biological plausibility that, in South
Asians, homocysteine owing to its prothrombotic effects and
interaction with conventional risk factors may increase the pro-
pensity of this population to develop coronary atherothrombotic
disease (11). According to one estimate, in Pakistan nearly 100,000
individuals suffered from acute myocardial infraction in calendar
year 2002 (12). These observations are undermined especially in
meta-analyses as a majority of the studies are done in the
population with lower mean homocysteine values. The sample size
in the meta-analysis of patients with homocysteine 15 mol/l
and especially in the range of 19 mol/l is not powered to give
statistically significant conclusions. This observation is obvious in
the high-impact trials like HOPE (Heart Outcome Prevention
Evaluation)-2 and NORVIT (Norwegian Vitamin Trial), where
the mean homocysteine values of patients were 12.2 mol/l and
13.0 mol/l, respectively (13,14). In view of the mandated
fortification of food products in the U.S., it was predicted
beforehand that the statistical power of the ongoing trials would be
marked by power shortage (15).
Ironically, the trend-setting study “Folate Therapy and In-Stent
Restenosis After Coronary Stenting” (16) in its conclusion never
mentioned the trend toward the beneficial effect of folate replace-
ment in patients with homocysteine levels 15 mol/l, and the
study became a landmark trial showing increase risk of in-stent
restenosis with folate therapy, which was documented in patients
with homocysteine levels 15 mol/l.
The scenario is further biased by the fact that after folic acid
fortification in the United States, a population-wide reduction in
blood homocysteine concentration has been seen; according to one
estimate, the proportion of patients with homocysteine 15
mol/l decreased from 41% to 28%. This mean decrease in
homocysteine levels in this population has nicely translated in
terms of trend toward mortality benefit in cardiovascular disease
and definite improvement in stroke-related mortality (17,18).
These facts are well appreciated by Kaul et al. in defining the
therapeutic range of high-risk individuals in the recommendations
for screening and treatment of elevated homocysteine levels.
How do developing countries, which form a major chunk of
global burden (2) of cardiovascular disease, reconcile with the
invalidation of homocysteine hypothesis for atherothrombosis? In
the long run, its repercussions could be in the form of the 10/90
gap, which refers to the global situation where only 10% of billions
of dollars is devoted to health research, which accounts for 90% of
total health burden (19).
Finally, this state-of-the-art study is food for thought in context
to the philosophy to achieve maximum diversity nicely highlighted
by Anthony DeMaria in the Journal’s Editor’s Page, “Diversity in
JACC ” (20).
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Reply
The data from the 3 largest completed trials of homocysteine
lowering with folic acid and vitamin B12 with or without vitamin B6
(VISP [Vitamin Intervention for Stroke Prevention] [1], NORVIT
[Norwegian Vitamin Trial] [2], and HOPE-2 [Heart Outcomes
Prevention Evaluation] [3]) consistently demonstrate no treatment
benefit in patients with established vascular disease. These trials
primarily evaluated white, middle-aged patients exposed to folate-
fortified food (70% in HOPE-2, 100% in VISP) with only mild
increases in homocysteine levels (15 mol/l). We agree that
homocysteine-lowering therapy might potentially still prove to be
beneficial in populations other than those studied—for example, in
Southeast Asian patients where homocysteine levels typically
exceed 15 mol/l related to genetic or dietary factors, as suggested
by Dr. Akhtar. However, subgroup analyses of the NORVIT and
HOPE-2 trials provide useful insights. In 40% of patients in the
NORVIT trial with a baseline homocysteine level above 13 mol/l
(mean homocysteine level was 17.4 mol/l in this subgroup),
homocysteine-lowering therapy provided no benefit. Similarly, no
treatment benefit was observed among patients in the upper fifth of
the baseline homocysteine distribution (19.7 mol/l) in
HOPE-2. It is quite possible that this lack of benefit may be
related to inadequate statistical power in these subgroups. Thus,
whether homocysteine-lowering therapy is going to be beneficial
cannot be answered definitively until prospective, randomized
trials are conducted in these populations. Ongoing large trials that
are currently exploring these issues and the planned meta-analyses
of all trials (12 trials involving about 52,000 participants with
adequate statistical power, 7 in populations without fortification,
and 5 in populations with fortification) (4) might help answer
remaining relevant clinical questions.
With regards to folate therapy and in-stent restenosis, we do
mention in our article (5) (p. 916) that slight, but not significant,
benefits were observed in patients with elevated homocysteine
levels (27.2% vs. 31.7%; p  NS).
A causal link between recent trends toward a lower rate of death
from stroke in the U.S. and Canada and the fortification of food
with folic acid remains speculative, as many other factors may have
contributed to the decline (6).
Finally, we agree with Dr. Akhtar that a major obstacle to
developing tools that address health problems of people in devel-
oping countries is the so-called 10/90 problem, whereby 90% of
health research expenditure is targeted at problems affecting only
10% of the world’s population. Investment in health, both at the
individual country level and at a global level, should therefore be
encouraged to provide the necessary resources to develop these
tools and enhance public health.
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